Interactions between μ-opioid receptor agonists and cannabinoid receptor agonists in rhesus monkeys: Antinociception, drug discrimination, and drug self-administration

Journal of Pharmacology and Experimental Therapeutics

Volumn 345, Issue 3, 2013, Pages 354-362

  Maguire, David R ^a   Yang, Wenjuan ^a   France, Charles P ^a  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; DIAMORPHINE; MORPHINE;

ANIMAL EXPERIMENT; ANTINOCICEPTION; ARTICLE; CONTROLLED STUDY; DISCRIMINATIVE STIMULUS; DOSE RESPONSE; DRUG DISCRIMINATION; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG SELF ADMINISTRATION; FEMALE; LATENT PERIOD; MALE; NONHUMAN; PRIORITY JOURNAL; REINFORCEMENT; RHESUS MONKEY;

ANALGESICS; ANALGESICS, OPIOID; ANIMALS; BENZOXAZINES; CANNABINOID RECEPTOR AGONISTS; CYCLOHEXANOLS; DATA INTERPRETATION, STATISTICAL; DISCRIMINATION (PSYCHOLOGY); DOSE-RESPONSE RELATIONSHIP, DRUG; DRONABINOL; HEROIN DEPENDENCE; HOT TEMPERATURE; MACACA MULATTA; MORPHINE; MORPHOLINES; NAPHTHALENES; PAIN MEASUREMENT; RECEPTORS, CANNABINOID; RECEPTORS, OPIOID, MU; SELF ADMINISTRATION;

EID: 84878080284     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.113.204099     Document Type: Article

References (48)

1. Ballantyne JC and Shin NS (2008) Efficacy of opioids for chronic pain: A review of the evidence. Clin J Pain 24:469-478.
2. Bowen CA, Fischer BD, Mello NK, and Negus SS (2002) Antagonism of the antinociceptive and discriminative stimulus effects of heroin and morphine by 3-methoxynaltrexone and naltrexone in rhesus monkeys. J Pharmacol Exp Ther 302: 264-273.
3. Breivogel CS and Childers SR (2000) Cannabinoid agonist signal transduction in rat brain: Comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J Pharmacol Exp Ther 295:328-336.
4. Bushlin I, Rozenfeld R, and Devi LA (2010) Cannabinoid-opioid interactions during neuropathic pain and analgesia. Curr Opin Pharmacol 10:80-86.
5. Cichewicz DL (2004) Synergistic interactions between cannabinoid and opioid analgesics. Life Sci 74:1317-1324.
6. ComptonWM and Volkow ND (2006) Major increases in opioid analgesic abuse in the United States: Concerns and strategies. Drug Alcohol Depend 81:103-107.
7. Doty P, Dykstra LA, and Picker MJ (1994) Discriminative stimulus effects of phencyclidine: Pharmacologically specific interactions with delta 9-and delta 8-tetrahydrocannabinol. Drug Alcohol Depend 35:151-158.
8. Dykstra LA and Woods JH (1986) A tail withdrawal procedure for assessing analgesic activity in rhesus monkeys. J Pharmacol Methods 15:263-269.
9. Finn DP, Beckett SRG, Roe CH, Madjd A, Fone KCF, Kendall DA, Marsden CA, and Chapman V (2004) Effects of coadministration of cannabinoids and morphine on nociceptive behaviour, brain monoamines and HPA axis activity in a rat model of persistent pain. Eur J Neurosci 19:678-686.
10. Gaskin DJ and Richard P (2012) The economic costs of pain in the United States. J Pain 13:715-724.
11. Gauvin DV and Young AM (1989) Evidence for perceptual masking of the discriminative morphine stimulus. Psychopharmacology (Berl) 98:212-221.
12. Gerak LR, Butelman ER, Woods JH, and France CP (1994) Antinociceptive and respiratory effects of nalbuphine in rhesus monkeys. J Pharmacol Exp Ther 271: 993-999.
13. Greenwald MK and Stitzer ML (2000) Antinociceptive, subjective and behavioral effects of smoked marijuana in humans. Drug Alcohol Depend 59:261-275.
14. Gutstein H and Akil H (2005) Opioid analgesics, in The pharmacological basis of therapeutics (Brunton L, Lazo J, and Parker K, eds, ed) pp 547-590, McGraw-Hill, New York.
15. Haney M (2007) Opioid antagonism of cannabinoid effects: Differences between marijuana smokers and nonmarijuana smokers. Neuropsychopharmacology 32: 1391-1403.
16. Haney M, Bisaga A, and Foltin RW (2003) Interaction between naltrexone and oral THC in heavy marijuana smokers. Psychopharmacology (Berl) 166:77-85.
17. Hosking RD and Zajicek JP (2008) Therapeutic potential of cannabis in pain medicine. Br J Anaesth 101:59-68.
18. Ko M-C and Woods JH (1999) Local administration of delta9- tetrahydrocannabinol attenuates capsaicin-induced thermal nociception in rhesus monkeys: A peripheral cannabinoid action. Psychopharmacology (Berl) 143:322-326.
19. Kraft B (2012) Is there any clinically relevant cannabinoid-induced analgesia? Pharmacology 89:237-246.
20. Lecca D, Cacciapaglia F, Valentini V, Acquas E, and Di Chiara G (2007) Differential neurochemical and behavioral adaptation to cocaine after response contingent and noncontingent exposure in the rat. Psychopharmacology (Berl) 191:653-667.
21. Li J-X, McMahon LR, Gerak LR, Becker GL, and France CP (2008) Interactions between D(9)-tetrahydrocannabinol and mu opioid receptor agonists in rhesus monkeys: Discrimination and antinociception. Psychopharmacology (Berl) 199: 199-208.
22. Li J-X, Koek W, and France CP (2012) Interactions between D(9)-tetrahydrocannabinol and heroin: Self-administration in rhesus monkeys. Behav Pharmacol 23: 754-761.
23. Lichtman AH and Martin BR (2005) Cannabinoid tolerance and dependence. Handb Exp Pharmacol 168:691-717.
24. Lile JA, Kelly TH, Pinsky DJ, and Hays LR (2009) Substitution profile of D9-tetrahydrocannabinol, triazolam, hydromorphone, and methylphenidate in humans discriminating D9-tetrahydrocannabinol. Psychopharmacology (Berl) 203: 241-250.
25. Manchikanti L and Singh A (2008) Therapeutic opioids: A ten-year perspective on the complexities and complications of the escalating use, abuse, and nonmedical use of opioids. Pain Physician 11(2, Suppl)S63-S88.
26. Manning BH, Merin NM, Meng ID, and Amaral DG (2001) Reduction in opioid-and cannabinoid-induced antinociception in rhesus monkeys after bilateral lesions of the amygdaloid complex. J Neurosci 21:8238-8246.
27. Manzanedo C, Aguilar MA, Rodríguez-Arias M, Navarro M, and Miñarro J (2004) Cannabinoid agonist-induced sensitisation to morphine place preference in mice. Neuroreport 15:1373-1377.
28. McMahon LR (2006) Characterization of cannabinoid agonists and apparent pA2 analysis of cannabinoid antagonists in rhesus monkeys discriminating D9-tetrahydrocannabinol. J Pharmacol Exp Ther 319:1211-1218.
29. McMahon LR (2011) Chronic D?-tetrahydrocannabinol treatment in rhesus monkeys: Differential tolerance and cross-tolerance among cannabinoids. Br J Pharmacol 162:1060-1073.
30. Miller LL, Picker MJ, Umberger MD, Schmidt KT, and Dykstra LA (2012) Effects of alterations in cannabinoid signaling, alone and in combination with morphine, on pain-elicited and pain-suppressed behavior in mice. J Pharmacol Exp Ther 342: 177-187.
31. Narang S, Gibson D, Wasan AD, Ross EL, Michna E, Nedeljkovic SS, and Jamison RN (2008) Efficacy of dronabinol as an adjuvant treatment for chronic pain patients on opioid therapy. J Pain 9:254-264.
32. Norwood CS, Cornish JL, Mallet PE, and McGregor IS (2003) Pre-exposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. Eur J Pharmacol 465: 105-114.
33. Pertwee RG (2001) Cannabinoid receptors and pain. Prog Neurobiol 63:569-611.
34. Reche I, Fuentes JA, and Ruiz-Gayo M (1996) Potentiation of delta 9-tetrahydrocannabinol-induced analgesia by morphine in mice: Involvement of m-and k-opioid receptors. Eur J Pharmacol 318:11-16.
35. Smith HS (2008) Combination opioid analgesics. Pain Physician 11:201-214.
36. Smith FL, Cichewicz D, Martin ZL, and Welch SP (1998) The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. Pharmacol Biochem Behav 60:559-566.
37. Solinas M and Goldberg SR (2005) Involvement of mu-, delta-and kappa-opioid receptor subtypes in the discriminative-stimulus effects of delta-9-tetrahydrocannabinol (THC) in rats. Psychopharmacology (Berl) 179:804-812.
38. Solinas M, Panlilio LV, Antoniou K, Pappas LA, and Goldberg SR (2003) The cannabinoid CB1 antagonist N-piperidinyl-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methylpyrazole-3-carboxamide (SR-141716A) differentially alters the reinforcing effects of heroin under continuous reinforcement, fixed ratio, and progressive ratio schedules of drug self-administration in rats. J Pharmacol Exp Ther 306:93-102.
39. Solinas M, Panlilio LV, Tanda G, Makriyannis A, Matthews SA, and Goldberg SR (2005) Cannabinoid agonists but not inhibitors of endogenous cannabinoid transport or metabolism enhance the reinforcing efficacy of heroin in rats. Neuropsychopharmacology 30:2046-2057.
40. Solinas M, Yasar S, and Goldberg SR (2007) Endocannabinoid system involvement in brain reward processes related to drug abuse. Pharmacol Res 56:393-405.
41. Tanda G, Munzar P, and Goldberg SR (2000) Self-administration behavior is maintained by the psychoactive ingredient of marijuana in squirrel monkeys. Nat Neurosci 3:1073-1074.
42. Viganò D, Rubino T, and Parolaro D (2005) Molecular and cellular basis of cannabinoid and opioid interactions. Pharmacol Biochem Behav 81:360-368.
43. Vivian JA, Kishioka S, Butelman ER, Broadbear J, Lee KO, and Woods JH (1998) Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in rhesus monkeys: Antagonist effects of SR 141716A. J Pharmacol Exp Ther 286: 697-703.
44. Walker JM and Hohmann AG (2005) Cannabinoid mechanisms of pain suppression. Handb Exp Pharmacol 168:509-554.
45. Welch SP (2009) Interaction of the cannabinoid and opioid systems in the modulation of nociception. Int Rev Psychiatry 21:143-151.
46. Welch SP and Stevens DL (1992) Antinociceptive activity of intrathecally administered cannabinoids alone, and in combination with morphine, in mice. J Pharmacol Exp Ther 262:10-18.
47. Wiley JL, Huffman JW, Balster RL, and Martin BR (1995a) Pharmacological specificity of the discriminative stimulus effects of delta 9- tetrahydrocannabinol in rhesus monkeys. Drug Alcohol Depend 40:81-86.
48. Wiley JL, Lowe JA, Balster RL, and Martin BR (1995b) Antagonism of the discriminative stimulus effects of delta 9-tetrahydrocannabinol in rats and rhesus monkeys. J Pharmacol Exp Ther 275:1-6.